Related Experiment Video
Updated: May 15, 2026
07:00
Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
Published on: February 28, 2019
Sinonasal NK/T-cell lymphoma
M Hmidi1, M Kettani, A Elboukhari
1Service ORL et chirurgie cervico-faciale, hôpital militaire My Ismaïl, boulevard El Hanssali, Meknès, Morocco. mounirhmidi@hotmail.com
European Annals of Otorhinolaryngology, Head and Neck Diseases
|January 1, 2013
Summary
Nasal NK/T-cell lymphoma is a rare aggressive cancer. Early diagnosis via immunohistochemistry and multidisciplinary treatment, including chemotherapy and radiotherapy, can lead to remission.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Nasal NK/T-cell lymphoma is a rare entity, recognized by the WHO in 2001.
- Immunohistochemistry aids in diagnosing this lymphoma, distinguishing it from conditions like Wegener's granulomatosis.
- Prognosis is generally poor due to aggressive nature and potential for rapid progression.
Observation:
- A 54-year-old male presented with bilateral nasal obstruction and purulent rhinorrhea.
- Diagnosis was confirmed through immunohistochemical analysis of biopsy samples.
- The tumor was staged as IE according to the Ann Arbor classification.
Findings:
- Treatment with CHOP chemotherapy followed by radiotherapy resulted in complete remission.
- Remission was sustained at an 8-month follow-up.
- Diagnosis relies on immunophenotypic and molecular profiling.
Implications:
- Sinonasal NK/T-cell lymphoma requires a multidisciplinary approach for effective management.
- Despite poor prognosis, successful treatment leading to remission is achievable.
- Further research into optimal treatment strategies for this rare lymphoma is warranted.
